secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001437749-22-018894
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotech swings to Q2 profit of $0.21/sh; NERLYNX revenue up 5%
-------------------------------------------------------------------

- GAAP net income $9.4M ($0.21 per share) vs net loss of $5.1M ($0.13 loss) in Q2 2021.
- Total revenue $59.5M ($51.3M product, $8.2M royalties) vs $53.4M in Q2 2021.
- Operating expenses fell sharply: SG&A $20.6M (down 48%), R&D $11.9M (down 36%).
- Cash and securities $60.8M at June 30, down from $82.1M at Dec 31, 2021.
- Management guides for FDA meetings on registration pathways for neratinib in H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922018894/0001437749-22-018894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922018894/pbyi20220802_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-018894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer